Boehringer submits CTA to initiate Phase I Alzheimer’s study
In January 2007, Boehringer and Ablynx entered into research and licensing agreement to discover new therapies for Alzheimer’s disease. The nanobody, developed under the collaboration, triggered a €1m
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.